Literature DB >> 3203329

The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders.

N Schoenfeld1, O Epstein, M Lahav, R Mamet, M Shaklai, A Atsmon.   

Abstract

The metabolism of heme is impaired in lymphocytes of patients with malignant lymphoproliferative disorders (MLPO). Two of the enzymes of the heme biosynthetic pathway, delta-aminolevulinic acid dehydrase (ALAD) (EC 4.2.1.24) and ferrochelatase (FC) (EC 4.99.1.1) are markedly reduced. The activity of porphobilinogen deaminase (PBGD) (EC 4.3.1.8) is increased. The rate-limiting enzyme of heme biosynthesis in the liver, aminolevulinate synthase (ALAS) (EC 2.3.1.37) remains unchanged although the concentration of total heme in the lymphocytes is markedly reduced. This might reflect a lack of negative feedback inhibition by heme on ALAS activity in this system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203329     DOI: 10.1016/0304-3835(88)90211-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin.

Authors:  R Schulten; B Novak; B Schmitz; H Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-17       Impact factor: 3.000

Review 3.  Current concepts in gastrointestinal photodynamic therapy.

Authors:  J Webber; M Herman; D Kessel; D Fromm
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

4.  Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX.

Authors:  Frank Duffner; Rainer Ritz; Dirk Freudenstein; Michael Weller; Klaus Dietz; Johannes Wessels
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 5.  Current status of photodynamic therapy in oncology.

Authors:  R van Hillegersberg; W J Kort; J H Wilson
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

6.  Poly(L-histidine)-tagged 5-aminolevulinic acid prodrugs: new photosensitizing precursors of protoporphyrin IX for photodynamic colon cancer therapy.

Authors:  Renjith P Johnson; Chung-Wook Chung; Young-Il Jeong; Dae Hwan Kang; Hongsuk Suh; Il Kim
Journal:  Int J Nanomedicine       Date:  2012-05-17

7.  Factors affecting aminolaevulinic acid-induced generation of protoporphyrin IX.

Authors:  L Wyld; J L Burn; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Photodynamic therapy using intravenous delta-aminolaevulinic acid-induced protoporphyrin IX sensitisation in experimental hepatic tumours in rats.

Authors:  K Svanberg; D L Liu; I Wang; S Andersson-Engels; U Stenram; S Svanberg
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

9.  Homology modeling of human γ-butyric acid transporters and the binding of pro-drugs 5-aminolevulinic acid and methyl aminolevulinic acid used in photodynamic therapy.

Authors:  Yan Baglo; Mari Gabrielsen; Ingebrigt Sylte; Odrun A Gederaas
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

10.  The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells.

Authors:  K Berg; H Anholt; O Bech; J Moan
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.